jk 05

Drug Profile

jk 05

Alternative Names: jk-05

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Academy of Military Medical Sciences
  • Developer Sihuan Pharmaceutical Holdings Group
  • Class Antivirals; Small molecules
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bunyavirus infections; Influenza virus infections; Viral haemorrhagic fevers; Yellow fever
  • No development reported Ebola virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Ebola-virus-infections in China
  • 06 Oct 2014 Sichuan Pharma acquires jk 05 from the Academy of Military Medical Sciences
  • 06 Oct 2014 Preclinical trials in Bunyavirus infections, Influenza virus infections, Viral haemorrhagic fevers, Yellow fever in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top